GW Pharmaceuticals PLC (OTC: GWPRF) is listed on the NASDAQ with an American depository (ADR) price above $100. However, the company also offers shares over the counter in the U.S. at a much lower price. For a relative bargain, it’s possible to invest in this rapidly growing cannabis pharmaceutical company.
GW Pharmaceuticals was the first and so far only company to receive FDA approval for a cannabis-derived drug. Epidiolex is a novel treatment for seizures caused by Lennox-Gastaut Syndrome. Sales are projected to increase significantly this year, with most analysts confident that revenue growth will exceed 80%. The company is heading towards positive earnings, which is likely to occur in 2021. The company’s ADR listing is up 16% in the year to date, and this over the counter offering is not far behind.
In the long term, analysts expect this stock to exceed the performance of its ADR listing. All 16 analysts surveyed by FactSet recommend a BUY rating, with an average target price of $188.63. The potential upside here is huge. As a Canadian-based company where the stock market is heavily regulated, this over the counter stock carries little of the risk that other foreign picks do.
For its potential and rapid strides in cannabis-based medicine, this is a top pick for alternative investors.
- 1 Year Price Growth: -29.06%
- YTD Price Growth: 10%
- 3 Month Price Growth: 97%
All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.